Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice

Mirna Lechpammer, Xiangjun Xu, F. Henry Ellis, Nandita Bhattacharaya, Geoffrey I. Shapiro, Massimo Loda

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


The cyclin-dependent kinase (cdk) inhibitor p27 preferentially inactivates cdk complexes required for progression through the G1/S transition. Loss of p27 is associated with aggressive behavior in a variety of tumors, including Barrett's associated adenocarcinoma (BAA). We have previously shown that gastroduodenal-esophageal reflux (GDER) together with N-methyl-N- benzylnitrosamine (MBN) induces Barrett's esophagus (BE) and malignant transformation of the esophageal mucosa in mice. This process is enhanced in a p27 null background. Here, we show that chronic flavopiridol administration sharply reduced the prevalence of BE in GDER/MBN-treated p27 knockout mice when compared to animals treated with diluent only (7 vs 26%, P = 0.0079). Similarly, flavopiridol reduced the prevalence of BAA (11 vs 32%, P = 0.0098) and overall cancer prevalence (15 vs 60%, P < 0.0001). In addition, appropriate molecular targeting by flavopiridol in tumor cells was confirmed by down-regulation of cyclin D1, a known target of this pan-cdk inhibitor. The results of this study represent the experimental basis for chemoprevention with cdk inhibitors in human BE and BAA.

Original languageEnglish (US)
Pages (from-to)1683-1688
Number of pages6
Issue number10
StatePublished - Mar 3 2005
Externally publishedYes


  • Barrett's associated adenocarcinoma
  • Barrett's esophagus
  • Flavopiridol
  • Mouse model
  • p27

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics


Dive into the research topics of 'Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice'. Together they form a unique fingerprint.

Cite this